Vanguard Group Inc. Raises Stake in Delcath Systems, Inc. $DCTH

Key Points

• Vanguard Group Inc. has increased its stake in Delcath Systems by 13.8% to own approximately 4.17% of the company's stock, valued at $17.7 million.
• Delcath Systems reported an EPS of $0.07 for the quarter, exceeding analysts' expectations, with revenues reaching $24.16 million.
• Wall Street analysts have mixed ratings on Delcath Systems, with price targets ranging from $25.00 to $31.00 and a consensus rating of "Buy".

Vanguard Group Inc. boosted its holdings in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 13.8% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,394,028 shares of the company's stock after buying an additional 169,260 shares during the period. Vanguard Group Inc. owned 4.17% of Delcath Systems worth $17,746,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Baader Bank Aktiengesellschaft boosted its stake in shares of Delcath Systems by 46.7% in the first quarter. Baader Bank Aktiengesellschaft now owns 24,903 shares of the company's stock worth $317,000 after acquiring an additional 7,925 shares during the period. Palisades Investment Partners LLC boosted its stake in Delcath Systems by 1.0% in the 1st quarter. Palisades Investment Partners LLC now owns 171,084 shares of the company's stock worth $2,178,000 after purchasing an additional 1,757 shares during the period. Principal Financial Group Inc. boosted its stake in Delcath Systems by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company's stock worth $1,497,000 after purchasing an additional 2,437 shares during the period. Cannon Global Investment Management LLC bought a new stake in shares of Delcath Systems during the first quarter valued at approximately $239,000. Finally, Capital Advisors Wealth Management LLC bought a new stake in shares of Delcath Systems during the first quarter valued at approximately $891,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Trading Up 1.8%

Shares of NASDAQ:DCTH traded up $0.20 during trading on Thursday, reaching $11.10. The company's stock had a trading volume of 298,741 shares, compared to its average volume of 613,935. The stock has a market capitalization of $388.28 million, a PE ratio of 222.00 and a beta of 0.85. Delcath Systems, Inc. has a 12 month low of $8.08 and a 12 month high of $18.23. The firm's 50 day simple moving average is $11.29 and its two-hundred day simple moving average is $12.93.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.05. The business had revenue of $24.16 million for the quarter, compared to the consensus estimate of $22.84 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. Research analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on DCTH shares. Wall Street Zen cut shares of Delcath Systems from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. HC Wainwright increased their price objective on shares of Delcath Systems from $29.00 to $31.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Finally, Stephens reaffirmed an "overweight" rating and issued a $25.00 target price on shares of Delcath Systems in a report on Monday, June 23rd. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $24.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.